Evelo Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
A live webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. An archived replay will be available for approximately 30 days following the presentation.
About
Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer, for which ten clinical readouts are expected during 2019 and 2020. Evelo is also advancing additional candidates through preclinical development in other disease areas.
For more information, please visit www.evelobio.com.
Contact
617-704-2333
stefan@evelobio.com
Source: Evelo Biosciences, Inc.